top of page

Pharmacotherapy for Postmenopausal Osteoporosis

JAMA. 2021;325(18):1888-1889. doi:10.1001/jama.2020.13841


According to a 2014 study, an estimated 44% (>40 million) of US adults aged 50 years or older in the US have osteoporosis (bone density T-score <−2.5) or low bone mass (T-score between −1 and −2.5) at the femoral neck or lumbar spine.1 Osteoporosis can be diagnosed by the occurrence of a fragility fracture (eg, hip or vertebral fracture) or by a bone density T-score below −2.5. US clinical guidelines recommend treatment of postmenopausal women who have osteoporosis.2 Despite significant adverse effects of fractures on morbidity and mortality, according to data published in 2011 only one-third of patients (18 902 of 60 275) who experienced hip fracture received osteoporosis pharmacotherapy within 12 months of hospital discharge.3


Read more here : https://jamanetwork.com/journals/jama/fullarticle/2779831?guestAccessKey=1b250e71-90c1-4e15-903d-555805d61d66&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=etoc&utm_term=051121

0 views0 comments

Recent Posts

See All
bottom of page